194 related articles for article (PubMed ID: 34431799)
21. Inclusion Body Myositis and Neoplasia: A Narrative Review.
Damian L; Login CC; Solomon C; Belizna C; Encica S; Urian L; Jurcut C; Stancu B; Vulturar R
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806366
[TBL] [Abstract][Full Text] [Related]
22. Inclusion Body Myositis.
Goyal NA
Continuum (Minneap Minn); 2022 Dec; 28(6):1663-1677. PubMed ID: 36537974
[TBL] [Abstract][Full Text] [Related]
23. Determination of cN1A Autoantibodies by Cell-Based Immunofluorescence Cytochemistry.
Yamashita S; Tawara N
Methods Mol Biol; 2019; 1901():89-94. PubMed ID: 30539570
[TBL] [Abstract][Full Text] [Related]
24. Inclusion body myositis.
Dimachkie MM; Barohn RJ
Neurol Clin; 2014 Aug; 32(3):629-46, vii. PubMed ID: 25037082
[TBL] [Abstract][Full Text] [Related]
25. Sporadic inclusion body myositis: new insights and potential therapy.
Machado PM; Dimachkie MM; Barohn RJ
Curr Opin Neurol; 2014 Oct; 27(5):591-8. PubMed ID: 25159931
[TBL] [Abstract][Full Text] [Related]
26. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
Lloyd TE; Christopher-Stine L; Pinal-Fernandez I; Tiniakou E; Petri M; Baer A; Danoff SK; Pak K; Casciola-Rosen LA; Mammen AL
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):66-71. PubMed ID: 25892010
[TBL] [Abstract][Full Text] [Related]
27. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG
J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871
[TBL] [Abstract][Full Text] [Related]
28. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
Lazarou IN; Guerne PA
J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
[TBL] [Abstract][Full Text] [Related]
29. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.
Yeker RM; Pinal-Fernandez I; Kishi T; Pak K; Targoff IN; Miller FW; Rider LG; Mammen AL;
Ann Rheum Dis; 2018 May; 77(5):714-719. PubMed ID: 29363513
[TBL] [Abstract][Full Text] [Related]
30. Inclusion body myositis.
Dimachkie MM; Barohn RJ
Semin Neurol; 2012 Jul; 32(3):237-45. PubMed ID: 23117948
[TBL] [Abstract][Full Text] [Related]
31. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment.
Needham M; Mastaglia FL
Clin Neurophysiol; 2016 Mar; 127(3):1764-73. PubMed ID: 26778717
[TBL] [Abstract][Full Text] [Related]
32. Update in inclusion body myositis.
Machado P; Brady S; Hanna MG
Curr Opin Rheumatol; 2013 Nov; 25(6):763-71. PubMed ID: 24067381
[TBL] [Abstract][Full Text] [Related]
33. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K; Granger B; Amelin D; Guiguet M; Hachulla E; Maurier F; Meyer A; Tohmé A; Charuel JL; Musset L; Allenbach Y; Benveniste O
JAMA Neurol; 2018 Dec; 75(12):1528-1537. PubMed ID: 30208379
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
[TBL] [Abstract][Full Text] [Related]
35. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility.
Herbert MK; Pruijn GJ
Curr Opin Rheumatol; 2015 Nov; 27(6):595-600. PubMed ID: 26285103
[TBL] [Abstract][Full Text] [Related]
36. Advances in serological diagnostics of inflammatory myopathies.
Benveniste O; Stenzel W; Allenbach Y
Curr Opin Neurol; 2016 Oct; 29(5):662-73. PubMed ID: 27538058
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies.
Lee SA; Lee HJ; Suh BC; Shin HY; Kim SW; Yoon BA; Choi YC; Park HJ
PLoS One; 2023; 18(4):e0284409. PubMed ID: 37058449
[TBL] [Abstract][Full Text] [Related]
38. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
Front Immunol; 2018; 9():1200. PubMed ID: 29922285
[TBL] [Abstract][Full Text] [Related]
39. [Polymyositis, dermatomyositis and inclusion body myositis, nosological aspects].
Eymard B
Presse Med; 2003 Oct; 32(35):1656-67. PubMed ID: 14631270
[TBL] [Abstract][Full Text] [Related]
40. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.
Hiniker A; Daniels BH; Lee HS; Margeta M
Acta Neuropathol Commun; 2013 Jul; 1():29. PubMed ID: 24252466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
